BAG2 and hepatocellular carcinoma: As shown in Figures 2J–L, HCC patients with high expression of BAG2 had significantly shorter overall survival (OS, p = 0.00012), progression free survival (PFS, p = 0.0029), and disease specific survival (DSS, p = 0.007).